Water soluble Pt(ii) complexes with higher viability towards normal cells and comparable cytotoxicity to cancer cells as compared to cisplatin.

Pd(ii) complexes with good DNA/BSA binding ability exhibit cytotoxicity comparable to cisplatin on different cancer cells along with reduced toxicity towards normal cells.

No abstract

Visible-light-active π-conjugated polymer photocatalysts can effectively harness solar energy, thereby offering pragmatic solutions to eclectic environmental issues. In the present study, a series of ingenious visible-light-responsive, stable, and recyclable modified polyimide (SWO 3 /PI) photocatalysts was synthesized via a facile microwave-assisted rapid thermal polymerization strategy. The precursors employed were pyromellitic dianhydride, melamine, thiourea, and tungsten trioxide co-catalyst. The template-free inclusion of sulfur and tungsten oxide species into the PI conformation increased visible-light absorption and enhanced the separation efficiency of the photogenerated electron−hole pairs. The visible-light-induced reactive red 120 (RR 120) photodegradation efficiency exhibited by the SWO 3 /PI photocatalyst was over 98% and was approximately 2.3 times higher than that exhibited by pristine PI. Herein h + and OH • were the principal active species involved in dye degradation. Interestingly, the sizable valence band edge downshift from 2.02 to 3.36 eV induced a remarkable enhancement in the photooxidation ability of the photoinduced holes, despite the fact that the relatively inappropriate position conduction band edge position (1.77 eV) did not favor the participation of photoinduced electrons in the reduction process. The liquid chromatography−mass spectrometry results revealed that photocatalytic degradation of RR 120 had been effectively accomplished.

No abstract

Cisplatin is known to induce Fanconi syndrome and renal salt wasting (RSW). RSW typically only requires transient normal saline (NS) support. We report a severe RSW case that required 12 liters of 3% saline. A 57-year-old woman with limited stage small cell cancer was admitted for cisplatin (80 mg/m2) and etoposide (100 mg/m2) therapy. Patient's serum sodium (SNa) decreased from 138 to 133 and 125 mEq/L within 24 and 48 hours of cisplatin therapy, respectively. A diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH) was initially made. Despite free water restriction, patient's SNa continued to decrease in association with acute onset of headaches, nausea, and dizziness. Three percent saline (3%S) infusion with rates up to 1400 mL/day was required to correct and maintain SNa at 135 mEq/L. Studies to evaluate Fanconi syndrome revealed hypophosphatemia and glucosuria in the absence of serum hyperglycemia. The natriuresis slowed down by 2.5 weeks, but 3%S support was continued for a total volume of 12 liters over 3.5 weeks. Attempts of questionable benefits to slow down glomerular filtration included the administration of ibuprofen and benazepril. To our knowledge, this is the most severe case of RSW ever reported with cisplatin.

In vitrodrug reservoir model reactions of thiols with novel Pt(ii) complex were investigated in aqueous medium and the complex and its substituted products show remarkable anticancer property.

In the aspect of an effective palladium based anticancer drug design, Pd(II) complexes [Pd(MAMP)Cl2], C1; [Pd(MAMP)(H2O)2]x2, C2; [Pd(MAMP)(L‐cys)]x, C3; [Pd(MAMP)(N‐ac‐L‐cys)], C4; [Pd(MAMP)(DL‐meth)]x2, C5; and [Pd(MAMP)(DL‐pen)]x, C6 (where x=ClO4−/NO3−) have been synthesised and characterised where 2‐[(methylamino)methyl]pyridine (MAMP) has been considered as carrier ligand and chloride, aqua, L‐cysteine (L‐cys), N‐acetyl‐L‐cysteine (N‐ac‐L‐cys), DL‐methionine (DL‐meth) and DL‐penicillamine (DL‐pen) are selected as leaving group. DNA as well as protein binding ability of the complexes has been investigated with CT‐DNA and BSA and the related binding parameters have been evaluated. Kinetic investigation for the reactions of Pd(II)‐diaqua complex C2 with four selected sulfur containing bio‐molecules have been carried out under pseudo first order condition. In addition, theoretical investigation has also been considered for structural optimisation, frontier molecular orbital mapping, TD‐DFT and NBO analysis. To get an insight into the cytotoxicity, the complexes have been treated on three different cancer cell lines (A549, HeLa, Hep G2) which reveal comparable anticancer activity of the reported complexes with the clinically acquainted anticancer drug Cisplatin. Very less complex initiated reactive oxygen species (ROS) with low degree of cell death in two different non‐tumour cell lines (L6 myotubes and HEK 293) indicate minimum normal cell toxicity of the complexes.